22. November - CCSF Investment Talk: Biotech Innovation - Made in Switzerland
Switzerland, as a center of biotech excellence, offers global reach, risk-conscious funding and scientific brilliance! We explore this interaction with people who are in the middle of it:
Dr. Stefanie Flückiger-Mangual, CEO, Tolremo - One of Tolremo's scientific founders and expert in the field of drug resistance in cancer therapy. She led the team of scientists who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.
Prof. Dr. Paul Herrling - he was one of the key scientific & business decision makers as Global Head of Research during his tenure at Novartis. He currently advises biotech venture funds and start-up companies.
Moderator: Dr Myoung-Ok Kwon - Head of Healthcare Investment, PMG Investment Solutions, Zürich
Start of event at 10:00 (Doors open at 09:45). Afterwards Networking, Kaffee und Gipfli.
The Investment Talk is in English.